Cargando…

Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives

Five percent of patients with cutaneous squamous cell carcinoma develop locally advanced or metastatic disease that is not amenable to definitive surgical or radiation therapy. Cemiplimab, an antibody against programmed death receptor-1, was approved in the United States for the treatment of locally...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mager, Layna, Gardeen, Samantha, Carr, David R, Shahwan, Kathryn T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423569/ https://www.ncbi.nlm.nih.gov/pubmed/37581012 http://dx.doi.org/10.2147/CCID.S381471

Ejemplares similares

Rapid response to cemiplimab for advanced cutaneous squamous cell carcinoma
por: Zargham, Hanieh, et al.
Publicado: (2022)

Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients
por: Van Meerhaeghe, T., et al.
Publicado: (2022)

Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma
por: Paul, Eleanor, et al.
Publicado: (2021)

Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside
por: Goodman, D.T.
Publicado: (2022)

Treatment of Unresectable Cutaneous Squamous Cell Carcinoma with Cemiplimab in a Patient on Dialysis
por: Grace de Lima, Stacy, et al.
Publicado: (2023)

Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
por: Lai, Fei Ya, et al.
Publicado: (2023)

Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion
por: Argenziano, Giuseppe, et al.
Publicado: (2022)

Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma
por: Virgen, Cesar A., et al.
Publicado: (2020)

Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios
por: Akhtar, Komal, et al.
Publicado: (2022)

IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
por: Mallardo, Domenico, et al.
Publicado: (2023)

Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma—A Retrospective Single-Center Study
por: Kuzmanovszki, Daniella, et al.
Publicado: (2023)

Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma
por: Marukian, Nareh Valerie, et al.
Publicado: (2020)

Efficacy of Cemiplimab in a Patient Affected by Cutaneous Squamous Cell Carcinoma and Myelodysplastic Syndrome
por: Proietti, Ilaria, et al.
Publicado: (2023)

Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy
por: Ghetti, Gianni, et al.
Publicado: (2021)

Intravascular squamous cell carcinoma treated with cemiplimab
por: Rose, Alexander N., et al.
Publicado: (2021)

Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
por: Rubatto, Marco, et al.
Publicado: (2021)

Cemiplimab for cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer
Publicado: (2022)

Case Report: Autoimmune Pemphigus Vulgaris in a Patient Treated With Cemiplimab for Multiple Locally Advanced Cutaneous Squamous Cell Carcinoma
por: Buquicchio, Rosalba, et al.
Publicado: (2021)

Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group
por: Hober, Candice, et al.
Publicado: (2021)

Anti‐PD‐1 therapy using cemiplimab for advanced cutaneous squamous cell carcinoma in HIV patient: A case report
por: Alloghbi, Abdurahman, et al.
Publicado: (2021)

Addendum: Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
por: Rubatto, Marco, et al.
Publicado: (2022)

Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic
por: Pabianek, Marta, et al.
Publicado: (2022)

Recurrent bilateral cutaneous squamous cell carcinoma arising within hypertrophic lichen planus with metastasis while on cemiplimab
por: Leeolou, Melissa C., et al.
Publicado: (2022)

Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study
por: Bailly-Caillé, Barbara, et al.
Publicado: (2023)

Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center
por: Denaro, Nerina, et al.
Publicado: (2023)

Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review
por: Banini, Marco, et al.
Publicado: (2023)

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
por: Rischin, Danny, et al.
Publicado: (2021)

Oral ulcers and sarcoid-like reaction in lymph nodes after cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma: a case report
por: Ferreira, Mariana Henriques, et al.
Publicado: (2022)

Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp
por: Paoluzzi, Luca, et al.
Publicado: (2021)

Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience
por: Rouvinov, Keren, et al.
Publicado: (2023)

The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports
por: Colombo, Elena, et al.
Publicado: (2023)

Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab
por: Siegel, Jacob D., et al.
Publicado: (2021)

Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy
por: Strippoli, Sabino, et al.
Publicado: (2021)

Advanced Squamous Cell Carcinoma Developed on Chronic Hidradenitis Suppurativa, Successfully Treated with Cemiplimab: A Case Report
por: Ruggiero, Angelo, et al.
Publicado: (2023)

Effective Management of Nasal Vestibule Squamous Cell Carcinoma with Cemiplimab: A Case Report
por: Costabile, Ferdinando, et al.
Publicado: (2023)

Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again
por: Davis, Christina M., et al.
Publicado: (2022)

Combined cemiplimab and radiotherapy for advanced basal cell carcinoma: A case report
por: Sarfaraz, Sidra, et al.
Publicado: (2023)

Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies
por: Yang, Feng, et al.
Publicado: (2021)

Cemiplimab-Induced Alopecia Areata
por: Piraccini, Bianca Maria, et al.
Publicado: (2023)

The Terrible Triad of Checkpoint Inhibition: A Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma
por: Jeyakumar, Nikeshan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2g6accij9eto3d6ahr1pdpeerc